| Identification | More | [Name]
Allylamine | [CAS]
107-11-9 | [Synonyms]
2-PROPEN-1-AMINE
2-PROPEN-1-YLAMINE
2-Propenamine
3-AMINO-1-PROPENE
3-AMINOPROPENE
AA
ALLYLAMINE
MONOALLYLAMINE
1-Aminoprop-2-ene
2-Propen-1-ylamin
2-Propene-1-amine
2-Propenylamine
3-Aminopropen
3-Aminopropylene
Allylamin
CH2=CHCH2NH2
prop-2-enylamine
ALLYLAMINE, 99+%
Allylamine, 98% (3-Amino-1-propene)
Allylamine, extra pure, 98+% | [EINECS(EC#)]
203-463-9 | [Molecular Formula]
C3H7N | [MDL Number]
MFCD00008199 | [Molecular Weight]
57.09 | [MOL File]
107-11-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Allylamine is a highly flammable, colorless liquid. Strong ammonia odor. | [Melting point ]
-88 °C (lit.) | [Boiling point ]
53 °C (lit.) | [density ]
0.763 | [vapor density ]
2 (vs air)
| [vapor pressure ]
4.09 psi ( 20 °C)
| [refractive index ]
n20/D 1.420(lit.)
| [Fp ]
−20 °F
| [storage temp. ]
Flammables area | [solubility ]
miscible with water, alcohol, chloroform and ether | [form ]
Crystalline or Granular Powder | [pka]
9.49(at 25℃) | [color ]
White or almost white | [Stability:]
Stability Air sensitive. Serious fire hazard. Highly flammable-note low flash point. May be ignited at temperatures close to ambient. | [Water Solubility ]
miscible | [Sensitive ]
Air Sensitive | [Merck ]
14,287 | [BRN ]
635703 | [Dielectric constant]
5.96 | [LogP]
0.13 at 20℃ | [CAS DataBase Reference]
107-11-9(CAS DataBase Reference) | [NIST Chemistry Reference]
2-Propen-1-amine(107-11-9) | [EPA Substance Registry System]
107-11-9(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
F,T,N | [Risk Statements ]
R11:Highly Flammable.
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed .
R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . | [Safety Statements ]
S9:Keep container in a well-ventilated place .
S16:Keep away from sources of ignition-No smoking .
S24/25:Avoid contact with skin and eyes .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S61:Avoid release to the environment. Refer to special instructions safety data sheet . | [RIDADR ]
UN 2334 6.1/PG 1
| [WGK Germany ]
2
| [RTECS ]
BA5425000
| [F ]
10 | [TSCA ]
Yes | [HazardClass ]
6.1 | [PackingGroup ]
I | [HS Code ]
29211980 | [Safety Profile]
Poison by inhalation, ingestion, intraperitoneal, and skin contact routes. Human systemic effects by inhalation: lacrymation and lung effects. A systemic irritant. Mutation data reported. A severe eye and skin irritant. Extraordnary precautions against fumes are advised. Dangerous fire and explosion hazard when exposed to heat, flame, or oxidzers. Highly reactive. When heated to decomposition it emits toxic fumes of NOx. To fight fire, use alcohol foam, CO2, dry chemical. See also ALLYL COMPOUNDS and AMINES. | [Hazardous Substances Data]
107-11-9(Hazardous Substances Data) | [Toxicity]
LD50 i.p. in mice: 49 mg/kg (Hine) |
| Hazard Information | Back Directory | [General Description]
A colorless to light yellow colored liquid with a strong ammonia-like odor. Less dense than water. Vapors are heavier than air. Toxic by inhalation, ingestion and skin absorption. Irritates skin, eyes and mucous membranes. Flash point below 0°F. Boiling point 130°F. Used to make pharmaceuticals and other chemicals. | [Reactivity Profile]
ALLYLAMINE(107-11-9) reacts violently with strong oxidizing agents and acids. Attacks copper and copper compounds [Handling Chemicals Safely 1980. p. 123]. Reacts with hypochlorites to give N-chloroamines, some of which are explosives when isolated [Bretherick 1979. p. 108]. | [Air & Water Reactions]
Highly flammable. Water soluble. | [Health Hazard]
Acute: an eye, skin, and respiratory tract irritant, which is highly toxic if inhaled or ingested and moderately toxic if absorbed on skin. Ingestion or inhalation may cause death or permanent injury after very short exposure to small quantities. Skin absorption may cause irreversible and reversible changes. Toxic air concentration (TClo) in humans is 5 ppm over 5 minutes. Vapors are extremely unpleasant and may ensure voluntary avoidance of dangerous concentrations. Will irritate nose and throat at 2.5 ppm. | [Potential Exposure]
Compound | [Fire Hazard]
Flammable when exposed to heat, sparks, or flame. Vapor forms explosive mixtures with air over a wide range. Use caution when approaching fire and applying water. Vapor explosion and poison hazard indoors, outdoors or in sewers. Runoff to sewer may create fire or explosion hazard. Can react with oxidizing materials. When heated to decomposition, ALLYLAMINE emits toxic fumes. Avoid oxidizing materials. Stable, avoid heating to decomposition. May become unstable at elevated temperatures and pressures or may react with water with non-violent release of energy. | [First aid]
If this chemical gets into the eyes, remove any contact lenses at once and irrigate immediately for at least 15 minutes, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts the skin, remove contaminated clothing and wash immediately with soap and water. Seek medical attention immediately. If this chemical has been inhaled, remove from exposure, begin rescue breathing (using universal precautions, including resuscitation mask) if breathing has stopped and CPR if heart action has stopped. Transfer promptly to a medical facility. When this chemical has been swallowed, get medical attention. Give large quantities of water and induce vomiting. Do not make an unconscious person vomit. Medical observation is recommended for 24 to 48 hours after breathing overexposure, as pulmonary edema may be delayed. As first aid for pulmonary edema, a doctor or authorized paramedic may consider administering a drug or other inhalation therapy. | [Shipping]
UN2334 Allylamine, Hazard class: 6.1; Labels: 6.1-Poison Inhalation Hazard, 3-Flammable liquids, Inhalation Hazard Zone B. | [Incompatibilities]
May form explosive mixture with air. Oxidizing materials and acids may cause a violent reaction. Attacks copper and corrodes active metals (i.e., aluminum, zinc, etc.). | [Description]
Allylamine is a primary unsaturated alkylamine and in this
review refers to monoallylamine. Allylamine can also be used
generically to describe the secondary (diallyl-) and tertiary
(triallyl-) amine derivatives of monoallylamine, as well as
other more complex alkylamines. Allylamine is a colorless,
flammable liquid and is volatile and reactive with oxidizing
materials. Allylamine has a strong ammonia odor, is acutely
toxic by all routes of exposure, and produces cardiotoxicity in
a manner that has been well characterized by in vivo and in vitro
methods. In addition to its use as an industrial chemical,
allylamine is utilized as a model compound for basic research
investigations into mechanisms of cardiovascular disease based
on the nature of the cardiac and vascular lesions observed
following allylamine exposure. | [Chemical Properties]
Allylamine is a highly flammable, colorless liquid. Strong ammonia odor. | [Chemical Properties]
Allylamine is highly reactive, combining the reactivity of amines with the unsaturation
of the allyl group (Schweizer et al 1978). Reaction with halogens, for
example, gives the corresponding halogenated propylamine in high yield. | [Chemical Properties]
colourless liquid | [Waste Disposal]
High temperature incineration; encapsulation by resin or silicate fixation. | [Uses]
Allylamine is used as an industrial solvent and in organic
synthesis, including rubber vulcanization, synthesis of ionexchange
resins, and as an intermediate in pharmaceutical
synthesis. Derivatives of allylamine are utilized as both veterinary
and human pharmaceuticals, including the antifungal
agent terbinafine. Allylamine has been used since the 1940s as
a research tool for investigations of cardiovascular disease, with
the earliest studies using allylamine to induce initial vascular
injury in animal models of atherogenesis. Additionally, allylamine
has been used to model myocardial infarction and
vascular injury in animal models of human cardiovascular
disease. | [Uses]
Allylamine ismanufactured fromallyl chloride andammonia.
It is used as a solvent and in organic syntheses, including the
synthesis of rubber, mercurial diuretics, sedatives, and antiseptics
(238). It is also used in the synthesis of ion-exchange
resins. | [Uses]
In the manufacture of mercurial diuretics. | [Definition]
ChEBI: Allylamine is an alkylamine. | [Production Methods]
Allylamine is produced by reaction of allyl chloride with ammonia. The amine is
also a natural constituent of foodstuffs (Shumkova and Karpova 1981; Mochalov
et al 1981) and is present in wastewater from oil shale retorting (Daughton et al
1985). | [Flammability and Explosibility]
Highlyflammable | [Industrial uses]
Allylamine is used in the synthesis of ion-exchange resins and for water-dispersible
copolymers useful for water purification and as flocculating agents
(Schweizer et al 1978). The amine is also used for the preparation of pharmaceuticals
including mercurial diuretics and antifungal agents (HSDB 1989). | [Environmental Fate]
Allylamine exposure results in myocardial damage and intimal
proliferation of vascular smooth muscle cells in multiple
animal species. The mechanism for these distinctive cardiovascular
lesions is believed to be related to its bioactivation to
acrolein and possibly hydrogen peroxide. Several lines of
evidence support this hypothesis; SSAO is highly active in
vascular tissue where allylamine predominantly distributes,
incubation of homogenates of vascular tissue with allylamine
results in the generation of acrolein and hydrogen peroxide,and pretreatment with a semicarbazide inhibitor of SSAO
reduces or eliminates the hypercontraction and vasospasm
associated with allylamine exposure in vitro. Researchers have
taken advantage of the distinctive lesions that result from
various exposures to allylamine and have used it as chemical
tool to induce animal models of cardiovascular dysfunction
that resemble human disease. | [Metabolism]
The uptake, tissue distribution, excretion and pharmacokinetics of a 450 mg/kg
oral dose of [14C]-allylamine has been studied over a 2 h period in male
Sprague-Dawley rats (Boor 1985). The amine was rapidly absorbed from the
gastrointestinal tract and quickly accumulated and then eliminated from tissues
with a short halflife of less than 1 h that seemed to fit a one compartment model.
The 14C-label was rapidly excreted in urine and no radioactivity was found in
feces. Allylamine or its metabolites showed an unusual predilection for accumulating
in elastic and muscular arteries with the highest radioactivity (5- to 10-fold
higher than most other organs) occurring in the aorta. Radioactivity in all other
tissues was generally much lower and fairly equal. At 5,10,15 and 20 min after an
i.v. dose of [14C]-allylamine, 30 to 33% of the admitted radioactivity was localized
in the aortas of adult Sprague-Dawley rats. By 30 min, 17% of the administered
dose was still present in that tissue (Hysmith and Boor 1985). Upon differential
centrifugation most of the radioactivity in the aorta was found to be localized in
the mitochondria. Further in vitro investigations (Hysmith and Boor 1987) showed
the specific binding of radioactivity from [14C]-allylamine to isolated rat aorta and
heart mitochondria at both high affinity and low affinity binding sites. As much as
23 and 43% of the bound radioactivity was covalently linked to aorta and heart
mitochondria, respectively. The monoamine oxidase B inhibitor, deprenyl, significantly
reduced both the specific and covalent binding of radioactivity from
[14C]-allylamine in phospholipase treated mitochondria while the benzylamine
oxidase inhibitor, semicarbazide, had no effect on [14C]-allylamine binding. These
results suggest that monoamine oxidase can convert allylamine to a highly reactive
metabolite that selectively covalently binds to heart mitochondria and that this
may explain the cardiotoxicity associated with this amine.
In vitro studies show that allylamine is converted by homogenates of various rat
tissues (heart, aorta, skeletal muscle, lung) to acrolein (Boor et al 1981; Nelson
and Boor 1982). Conversion of allylamine to acrolein in human tissue was 58, 8
and 6% in aorta, myocardium and liver, respectively, while in the rat the
percentages of acrolein formation were 95, 18, 9 and 5% in aorta, lung, skeletal
muscle, and heart preparations, respectively (Boor and Nelson 1982). Purified
bovine plasma amine oxidase and porcine kidney diamine oxidase converted
allylamine to acrolein in vitro (Nelson and Boor 1982). Studies with selective
inhibitors suggested that benzylamine oxidase is the active enzyme in oxidizing
allylamine. Inhibition of benzylamine oxidase with either semicarbazide or
phenelzine protected aortic smooth muscle cells from allylamine-induced cytolethal
injury (Hysmith and Boor 1988). Inhibition of benzylamine oxidase markedly
altered the subcellular distribution of radioactivity from [14C]-allylamine in aortic
smooth muscle cells, with the administered radioactivity no longer being localized
in the mitochondria. The sole urinary metabolite of allylamine in vivo has been
identified as 3-hydroxypropylmercapturic acid (Boor et al 1987; Kage and Young
1972). Parallel experiments showed glutathione (GSH) depletion in several
organs, the most marked occurring in aorta, blood and lung. These findings
indicate that allylamine was metabolized in vivo to the highly reactive aldehyde,
acrolein, which was subsequently converted to a mercapturic acid through a GSH
conjugation pathway. | [Purification Methods]
Purify allylamine by fractional distillation from calcium chloride. It causes sneezing and tears. [Beilstein 4 IV 1057.] | [Toxicity evaluation]
The production and use of allylamine as an industrial solvent
may result in environmental releases to the air, water, and soil.Allylamine is freely soluble in water, alcohol, chloroform,
and most solvents. The vapor pressure at 20°C is 198mm Hg,
the Henry’s law constant is estimated to be 9.95×10-6 atm
m3 mol-1, and the octanol/water partition coefficient (log Kow)
is estimated to be 0.21. |
|